Irene van der Horst-Bruinsma
Overview
Explore the profile of Irene van der Horst-Bruinsma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1188
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
van der Heijde D, Molto A, Ramiro S, Braun J, Dougados M, van Gaalen F, et al.
Ann Rheum Dis
. 2023 Dec;
83(5):547-549.
PMID: 38071514
Ankylosing spondylitis (AS) is the historic term used for decades for the HLA-B27-associated inflammatory disease affecting mainly the sacroiliac joints (SIJ) and spine. Classification criteria for AS have radiographic sacroiliitis...
12.
Eder L, James A, van der Horst-Bruinsma I, Coates L, Goel N
J Rheumatol
. 2023 Aug;
50(Suppl 2):38-40.
PMID: 37527854
Sex (biological attributes associated with being male or female) and gender (sociocultural-driven traits and behaviors related to being a man or a woman) are emerging as important determinants of disease...
13.
Boekel L, Atiqi S, Leeuw M, Hooijberg F, Besten Y, Wartena R, et al.
Lancet Rheumatol
. 2023 Jul;
5(7):e375-e385.
PMID: 37398978
Background: Studies on long-term consequences of COVID-19, commonly referred to as post-COVID condition, in patients with inflammatory rheumatic diseases are scarce and inconclusive. Furthermore, classifying patients with inflammatory rheumatic diseases...
14.
Treatment decisions in axial spondyloarthritis daily clinical practice are more than treat-to-target
Bolt J, Aalbers C, Walet L, van Mens L, van Denderen C, van der Horst-Bruinsma I, et al.
Rheumatology (Oxford)
. 2023 Apr;
63(1):34-40.
PMID: 37021937
Objective: 'Treat-to-target principles' are advised for axial spondyloarthritis (axSpA), although a clear target is not yet defined and targets do not always reflect inflammation. Treat-to-target use and motives for treatment...
15.
Ornbjerg L, Linde L, Georgiadis S, Rasmussen S, Lindstrom U, Askling J, et al.
Semin Arthritis Rheum
. 2022 Dec;
58:152141.
PMID: 36463635
No abstract available.
16.
Ornbjerg L, Rugbjerg K, Georgiadis S, Rasmussen S, Lindstrom U, Pavelka K, et al.
J Rheumatol
. 2022 Dec;
50(8):1009-1019.
PMID: 36455943
Objective: To investigate the distribution of patient-reported outcomes (PROs) in patients with axial spondyloarthritis (axSpA) initiating a tumor necrosis factor inhibitor (TNFi), to assess the proportion reaching PRO "remission" across...
17.
Ishigaki K, Sakaue S, Terao C, Luo Y, Sonehara K, Yamaguchi K, et al.
Nat Genet
. 2022 Nov;
54(11):1640-1651.
PMID: 36333501
Rheumatoid arthritis (RA) is a highly heritable complex disease with unknown etiology. Multi-ancestry genetic research of RA promises to improve power to detect genetic signals, fine-mapping resolution and performances of...
18.
Nissen M, Delcoigne B, Di Giuseppe D, Jacobsson L, Hetland M, Ciurea A, et al.
Rheumatology (Oxford)
. 2022 Mar;
61(12):4741-4751.
PMID: 35323903
Objectives: Many axial spondylarthritis (axSpA) patients receive a conventional synthetic DMARD (csDMARD) in combination with a TNF inhibitor (TNFi). However, the value of this co-therapy remains unclear. The objectives were...
19.
Christiansen S, Ornbjerg L, Rasmussen S, Loft A, Askling J, Iannone F, et al.
Rheumatology (Oxford)
. 2021 Dec;
61(9):3799-3807.
PMID: 34940840
Objectives: To investigate time trends in baseline characteristics and retention, remission and response rates in bio-naïve axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating TNF inhibitor (TNFi) treatment. Methods:...
20.
van der Horst-Bruinsma I, Miceli-Richard C, Braun J, Marzo-Ortega H, Pavelka K, Kivitz A, et al.
Rheumatol Ther
. 2021 Oct;
8(4):1775-1787.
PMID: 34618347
Introduction: Despite of higher disease burden, lower efficacy to biologics has been reported in female compared to male patients with ankylosing spondylitis (AS). The aim of this study was to...